[{"id":"88f3eaef-14f2-44c3-90f7-c4ebafee84e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474064","created_at":"2026-03-28T01:40:03.816Z","updated_at":"2026-03-28T01:40:03.816Z","phase":"Phase 2","brief_title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","source_id_and_acronym":"NCT07474064","lead_sponsor":"chenxu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/26/2026","start_date":" 03/26/2026","primary_txt":" Primary completion: 03/31/2031","primary_completion_date":" 03/31/2031","study_txt":" Completion: 03/31/2035","study_completion_date":" 03/31/2035","last_update_posted":"2026-03-17"},{"id":"0ad91159-5e74-4841-9bb6-f71f53c01cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07181720","created_at":"2025-09-20T07:06:00.818Z","updated_at":"2025-09-20T07:06:00.818Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial","source_id_and_acronym":"NCT07181720","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-09-18"},{"id":"1e3be90b-cc8d-4ccf-9c21-3f3fb2a8ae0a","acronym":"SEACLIFF","url":"https://clinicaltrials.gov/study/NCT07181161","created_at":"2025-09-20T07:05:48.306Z","updated_at":"2025-09-20T07:05:48.306Z","phase":"Phase 1/2","brief_title":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT07181161 - SEACLIFF","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD9574"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 09/22/2025","start_date":" 09/22/2025","primary_txt":" Primary completion: 01/09/2029","primary_completion_date":" 01/09/2029","study_txt":" Completion: 01/09/2029","study_completion_date":" 01/09/2029","last_update_posted":"2025-09-18"},{"id":"b8780b09-e2a8-40fb-8a41-38bd2486556e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07165236","created_at":"2025-09-13T08:40:34.118Z","updated_at":"2025-09-13T08:40:34.118Z","phase":"","brief_title":"Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor","source_id_and_acronym":"NCT07165236","lead_sponsor":"Osijek University Hospital","biomarkers":" IL4","pipe":"","alterations":" ","tags":["IL4"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/28/2024","start_date":" 11/28/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2025-09-10"},{"id":"23321d61-92f1-4817-9ef8-fa2c65366aec","acronym":"","url":"https://clinicaltrials.gov/study/NCT07134504","created_at":"2025-08-23T13:30:10.304Z","updated_at":"2025-08-23T13:30:10.304Z","phase":"","brief_title":"Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico.","source_id_and_acronym":"NCT07134504","lead_sponsor":"Instituto Mexicano del Seguro Social","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 07/20/2025","start_date":" 07/20/2025","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-08-21"},{"id":"6e77a79a-6073-4141-8dd8-cc4d9d61de69","acronym":"","url":"https://clinicaltrials.gov/study/NCT07101900","created_at":"2025-08-09T14:52:51.285Z","updated_at":"2025-08-09T14:52:51.285Z","phase":"Phase 2","brief_title":"68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses","source_id_and_acronym":"NCT07101900","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-08-08"},{"id":"66ccecbb-fe4e-496e-997f-7e4c2aa7798b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07080242","created_at":"2025-07-26T13:29:22.344Z","updated_at":"2025-07-26T13:29:22.344Z","phase":"Phase 1","brief_title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","source_id_and_acronym":"NCT07080242","lead_sponsor":"SystImmune Inc.","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-07-23"},{"id":"c93a00c7-3219-4e95-972d-b06d93f80607","acronym":"","url":"https://clinicaltrials.gov/study/NCT07050433","created_at":"2025-07-05T13:56:17.274Z","updated_at":"2025-07-05T13:56:17.274Z","phase":"","brief_title":"Correlate Biomarkers for the SYNERGY- 201 Study","source_id_and_acronym":"NCT07050433","lead_sponsor":"Duke University","biomarkers":" CXCR2","pipe":"","alterations":" ","tags":["CXCR2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-07-03"},{"id":"a53fa2e0-6d49-41e2-af0a-1261220c8c4d","acronym":"RIVERS","url":"https://clinicaltrials.gov/study/NCT07038928","created_at":"2025-06-28T13:38:50.236Z","updated_at":"2025-06-28T13:38:50.236Z","phase":"","brief_title":"TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation","source_id_and_acronym":"NCT07038928 - RIVERS","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-06-26"},{"id":"7152824f-51d6-434a-a17c-b34a21be5fde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07037004","created_at":"2025-06-28T13:42:45.741Z","updated_at":"2025-06-28T13:42:45.741Z","phase":"Phase 2","brief_title":"Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","source_id_and_acronym":"NCT07037004","lead_sponsor":"City of Hope Medical Center","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/04/2026","start_date":" 05/04/2026","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2025-06-25"},{"id":"3a8e94f4-0040-4f56-93f4-fd86db056dcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06879041","created_at":"2025-06-07T14:42:17.891Z","updated_at":"2025-06-07T14:42:17.891Z","phase":"Phase 1","brief_title":"A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT06879041","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 03/10/2025","start_date":" 03/10/2025","primary_txt":" Primary completion: 04/16/2029","primary_completion_date":" 04/16/2029","study_txt":" Completion: 04/16/2029","study_completion_date":" 04/16/2029","last_update_posted":"2025-06-04"},{"id":"16167a12-edc3-4776-9942-2975c9714e30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03258593","created_at":"2025-06-07T14:49:21.304Z","updated_at":"2025-06-07T14:49:21.304Z","phase":"Phase 1","brief_title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","source_id_and_acronym":"NCT03258593","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vicineum (oportuzumab monatox)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 10/17/2022","study_completion_date":" 10/17/2022","last_update_posted":"2025-05-30"},{"id":"ef3ee7ea-e266-49a7-bd2d-0c9eccee4dcb","acronym":"EvoPAR-PR02","url":"https://clinicaltrials.gov/study/NCT06952803","created_at":"2025-06-07T14:51:41.431Z","updated_at":"2025-06-07T14:51:41.431Z","phase":"Phase 3","brief_title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","source_id_and_acronym":"NCT06952803 - EvoPAR-PR02","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • saruparib (AZD5305)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 05/30/2025","start_date":" 05/30/2025","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 04/30/2036","study_completion_date":" 04/30/2036","last_update_posted":"2025-05-30"},{"id":"e32f44a1-6c83-4eeb-afea-f28ff7b0d2a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914794","created_at":"2025-08-02T14:12:26.243Z","updated_at":"2025-08-02T14:12:26.243Z","phase":"Phase 2","brief_title":"A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors","source_id_and_acronym":"NCT03914794","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FGFR3","pipe":"","alterations":" ","tags":["FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 10/02/2020","start_date":" 10/02/2020","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-05-21"},{"id":"9437d933-e07c-4a73-a4d1-9e685faabf3a","acronym":"PRIME","url":"https://clinicaltrials.gov/study/NCT06981377","created_at":"2025-09-07T01:39:46.192Z","updated_at":"2025-09-07T01:39:46.192Z","phase":"","brief_title":"PRostate Cancer Plasma Integrative Multi-modal Evaluation","source_id_and_acronym":"NCT06981377 - PRIME","lead_sponsor":"Santa Chiara Hospital","biomarkers":" BRCA2","pipe":"","alterations":" ","tags":["BRCA2"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-05-20"},{"id":"251e3807-7c32-48ca-b5d8-dd58192012fb","acronym":"DIVON","url":"https://clinicaltrials.gov/study/NCT06957561","created_at":"2025-09-07T01:29:15.570Z","updated_at":"2025-09-07T01:29:15.570Z","phase":"Phase 1/2","brief_title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT06957561 - DIVON","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Idafang (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-05-04"},{"id":"69f52b30-5163-4f46-8cbc-94e44a11b34d","acronym":"NYCRCCL","url":"https://clinicaltrials.gov/study/NCT06949215","created_at":"2025-09-07T01:25:44.584Z","updated_at":"2025-09-07T01:25:44.584Z","phase":"Phase 2","brief_title":"68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision","source_id_and_acronym":"NCT06949215 - NYCRCCL","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-04-29"},{"id":"067fae8a-0794-4faa-b039-26fcd91b764b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06842498","created_at":"2025-02-25T12:32:24.274Z","updated_at":"2025-02-25T12:32:24.274Z","phase":"Phase 2","brief_title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT06842498","lead_sponsor":"FibroGen","biomarkers":" CD46","pipe":"","alterations":" ","tags":["CD46"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FG-3246"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"164a11b6-0a88-4e66-b764-a14af3e3880e","acronym":"NCI-2018-01054","url":"https://clinicaltrials.gov/study/NCT03360721","created_at":"2021-01-18T16:35:16.869Z","updated_at":"2025-02-25T12:26:48.752Z","phase":"Phase 2","brief_title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT03360721 - NCI-2018-01054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" AR overexpression • AR expression • AR-V7 expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR overexpression • AR expression • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-24"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • Imunace (teceleukin) • MB-101"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Jingzhuda (entinostat) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"8c8f22b1-e6b8-42e7-9888-20229cd33cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04706663","created_at":"2021-01-19T20:51:39.257Z","updated_at":"2025-02-25T12:27:52.510Z","phase":"","brief_title":"Precision-Based Genomics in Prostate Cancer","source_id_and_acronym":"NCT04706663","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM","pipe":" | ","alterations":" TMB-H","tags":["TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-24"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • liposomal gemcitabine (FF-10832) • methotrexate IV • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez)"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"}]